Advertisement
Document › Details
Sofinnova Partners. (9/10/24). "Press Release: Sofinnova Partners Appoints Karl Naegler as Partner". Paris.
Region | Germany | |
Organisation | Sofinnova Partners SAS | |
Group | Sofinnova (Group) | |
Organisation 2 | Wellington Partners Venture Capital GmbH | |
Group | Wellington Partners (Group) | |
Product | venture capital | |
Product 2 | LIFE SCIENCES | |
Person | Nägler, Karl (Sofinnova 202409– Partner at S Partners before Wellington Partners + Gimv + Ventech + Atlas Venture) | |
Person 2 | Gkelou, Anta (Sofinnova 202409c– promotion to Partner from Principal) | |
Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments
Sofinnova Partners (“Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also marks Sofinnova’s expansion into Germany, bolstering its reach and influence across Europe.
Naegler will play a key role in Sofinnova Capital, the firm’s early-stage investment strategy, established 35 years ago. His expertise strengthens the firm’s commitment to championing early-stage innovation in life sciences and enhances a well-established team of partners.
Before joining Sofinnova, Naegler was a Managing Partner at Wellington Partners Life Sciences and a Partner at Gimv, where he was instrumental in the success of several high-profile startups, from company formation to successful exit. These include Seamless Therapeutics, recently launched with a top syndicate of investors, Breath Therapeutics, a co-investment with Sofinnova, acquired by Zambon, Covagen, acquired by Johnson & Johnson, and Prosonix, acquired by Circassia Pharmaceuticals.
"We’ve known and worked with Karl for two decades and his track record speaks for itself," said Graziano Seghezzi, Managing Partner, at Sofinnova Partners. "His deep industry knowledge, impeccable reputation, and strong relationship with Sofinnova make him an exceptional addition to the team. Karl’s appointment follows the recent promotion of Anta Gkelou, from Principal to Partner, further solidifying our team of senior partners."
"Sofinnova is a world-class firm that truly leads life sciences venture capital in Europe," Naegler said. "The opportunity to be part of an investment platform spanning multiple sectors, stages and geographies, with such a high-caliber team, was an opportunity I could not pass up. I look forward to bringing my experience to bear as we build and support the most innovative companies in life sciences across Europe while reinforcing our footprint in Germany."
Naegler’s career includes key roles at Ventech and Atlas Venture. He was also a Scientific Fellow at CNRS for Neurochemistry in Strasbourg and earned his Ph.D. in Molecular Neurobiology from the Max-Delbrück-Center for Molecular Medicine in Berlin.
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: sofinnovapartners.com.
Contacts
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
United Kingdom
Optimum Strategic Communications
Hana Malik
sofinnova@optimumcomms.com
+44 (0) 20 3882 2119
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavaraiext@havaspr.com
+39 (0) 392 77 999 33
DACH
MC Services AG
Katja Arnold, Kaja Skorka
sofinnova@mc-services.eu
+49-89-210 228-0
Record changed: 2024-10-08 |
Advertisement
More documents for Sofinnova (Group)
- [1] Purespring Therapeutics Ltd.. (10/9/24). "Press Release: Purespring Therapeutics Raises £80/$105 Million in a Series B Financing to Transform the Treatment of Kidney Diseases". London....
- [2] Genespire S.r.l.. (9/25/24). "Press Release: Genespire Raises €46.6 Million (~$52 Million) in a Series B Round to Advance Its First Pediatric in-vivo Gene Therapy into the Clinic". Milan....
- [3] Novameat Tech SL. (9/12/24). "Press Release: Novameat Raises €17.4M Oversubscribed Series A Round Led by Sofinnova Partners and Forbion". Barcelona....
- [4] Deepc GmbH. (7/24/24). "Press Release: Deepc Closes Series A Extension to Accelerate Global Deployment of Healthcare AI, Bringing Total Funding to $30m". Munich....
- [5] Endoron Medical Ltd.. (7/9/24). "Press Release: Endoron Medical Raises $10 Million in Series A Funding Led by Sofinnova Partners to Accelerate the Validation of Its AAA EndoStapling Solution Aortoseal". Tel Aviv....
- [6] Marea Therapeutics. (6/18/24). "Press Release: Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases". South San Francisco, CA....
- [7] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
- [8] Bioptimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
- [9] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
- [10] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top